Alimentation Couche-Tard Inc. (OTCMKTS:ANCTF – Get Free Report) shares crossed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $52.07 and traded as high as $52.49. Alimentation Couche-Tard shares last traded at $52.31, with a volume of 22,533 shares trading hands.
Analyst Upgrades and Downgrades
Several equities analysts have issued reports on the stock. Royal Bank Of Canada restated an “outperform” rating on shares of Alimentation Couche-Tard in a research note on Wednesday, September 3rd. Scotiabank restated an “outperform” rating on shares of Alimentation Couche-Tard in a research note on Thursday, September 4th. The Goldman Sachs Group upgraded shares of Alimentation Couche-Tard to a “hold” rating in a research note on Friday, September 12th. National Bankshares restated an “outperform” rating on shares of Alimentation Couche-Tard in a research note on Monday, August 18th. Finally, BMO Capital Markets cut shares of Alimentation Couche-Tard from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 19th. Three investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Alimentation Couche-Tard has an average rating of “Buy”.
Check Out Our Latest Stock Report on ANCTF
Alimentation Couche-Tard Stock Up 0.8%
Alimentation Couche-Tard Company Profile
Alimentation Couche-Tard Inc operates and licenses convenience stores in North America, Europe, and Asia. It offers cigarette products and other nicotine products, grocery items, candies and snacks, beer, wine, beverages, and fresh food offerings; road transportation fuels and electric vehicle charging solutions; and aviation fuels, as well as energy for stationary engines.
See Also
- Five stocks we like better than Alimentation Couche-Tard
- Trading Stocks: RSI and Why it’s Useful
- Palantir’s New Healthcare Deal Boosts AI and Data Reach
- What is Forex and How Does it Work?
- GM’s Billion-Dollar Bruise: GM’s Strategic Pivot Makes It a Buy
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead
Receive News & Ratings for Alimentation Couche-Tard Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimentation Couche-Tard and related companies with MarketBeat.com's FREE daily email newsletter.